Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence
Authors:
Open Access
- 20 January 2004
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (2) , 449-454
Abstract
Novel palliative strategies for patients with androgen-independent prostate cancer (AIPC) include targeting the epidermal growth factor receptor (EGFR) family. The aim of the present study was to investigate intrapatient changes of EGFRs during the development of AIPC. In total, 106 symptomatic AIPC patients were identified in whom prostatic biopsies (adenocarcinoma) were available both before the start of androgen deprivation (PRTR biopsy) and after the development of AIPC (AIPC biopsy). All four known subgroups of the EGFR family were determined by immunohistochemistry (IHC): c-erbB-1 (EGFR), c-erbB-2 (HER2/neu), c-erbB-3 (HER3) and c-erbB-4 (HER4). Moderate to strong membrane-specific staining was recorded semiquantitatively (vs ⩾ 10%=IHC stained tumour cells: ‘negative’ vs ‘positive’ staining). The medical records were reviewed for clinical variables. During the development of AIPC, intrapatient changes occurred in two opposite directions for each of the four EGFRs: negativity changed to positivity, and vice versa, statistically significant only for the increase of c-erbB-1 expression (P=0.001). The c-erbB-2 expression in the AIPC biopsy was associated with a significantly shorter survival from the time of the AIPC biopsy (P=0.029). Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer. Further research is needed to understand the function of EGFRs in this malignancy.Keywords
This publication has 27 references indexed in Scilit:
- Androgen-independent Prostate Cancer The Clinical Problem of a Growing Pelvic TumourActa Oncologica, 2003
- Regulation of Epidermal Growth Factor Receptor Internalization by G Protein-Coupled ReceptorsBiochemistry, 2003
- Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.2002
- Independent prognostic significance of HER‐2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapyInternational Journal of Cancer, 2002
- Growth factors and their receptors: new targets for prostate cancer therapyUrology, 2001
- A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.2001
- Hormone‐resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factorsBJU International, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinaseNature Medicine, 1999
- Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic CarcinomaJournal of Urology, 1993